Built on science. Run by operators.

Biomemory spun out of Sorbonne University and CNRS in 2021. Most players in DNA data storage hold one piece of the stack; Biomemory spans molecular biology, biochemistry, hardware, software, and industrial production in a single integrated platform, the hard part of this field. The same research lineage reached a sovereign milestone in 2021, when the French National Archives preserved two founding texts in DNA using the CNRS and Sorbonne science behind Biomemory, a technology reference rather than a customer or a deployment.

The decision since has been to industrialize that science rather than keep it in the laboratory. After the Catalog acquisition, Biomemory owns DNA production in Boston alongside its site in Paris. As of 7th September 2026, pending final country-level reconciliation. Biomemory's IP portfolio spans 21 patent families, with 53 patents already granted — across 10 of those families — and 84 further applications pending, for 137 total filings worldwide spanning encoding, synthesis, storage, retrieval, search, and compute. That owned production and consolidated IP is what a well-funded rival cannot buy quickly.

Biomemory is a leader in commercial DNA data storage and is a member of the DNA Data Storage Alliance, a SNIA Community. Biomemory's representative Vincent Franceschini is the current co-chair of the DDSA, and Chairman Emeritus of SNIA.